Myeloproliferative Neoplasms
Specialty Channel

Featured Article
True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.
Is there a significant link between serum ferritin level and fibrosis in older patients with MF?
Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.
Researchers have observed a significant link between serum ferritin level and fibrosis in older patients with MF.
True or False: A long-term survival advantage has been demonstrated with allogeneic HCT in certain patients with MF, at the expense of possible early death.
Which combo regimen did the PHAZAR trial confirm as being well-tolerated with comparable safety for patients with advanced-phase MPN/post-MPN AML?
Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.
True or False: Ruxolitinib plus azacitidine was not well-tolerated among patients with advanced phase MPN/post-MPN AML in the 1250 Phazar clinical trial.
True or false: Guadecitabine maintenance therapy after allogeneic stem cell transplantation has yielded promising survival rates and manageable safety in high-risk patients with MDS/AML.

News

Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.
Researchers have observed a significant link between serum ferritin level and fibrosis in older patients with MF.
Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.

Interactive Features

True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.
Is there a significant link between serum ferritin level and fibrosis in older patients with MF?
True or False: A long-term survival advantage has been demonstrated with allogeneic HCT in certain patients with MF, at the expense of possible early death.
Which combo regimen did the PHAZAR trial confirm as being well-tolerated with comparable safety for patients with advanced-phase MPN/post-MPN AML?
Stay in the know.
OncNet Newsletter